Page last updated: 2024-08-26

mizoribine and Familial Spastic Paraparesis, Htlv-1-Associated

mizoribine has been researched along with Familial Spastic Paraparesis, Htlv-1-Associated in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arimura, K; Higuchi, I; Izumo, S; Kawabata, M; Kubota, H; Maruyama, Y; Nakagawa, M; Nakahara, K; Osame, M1
Arimura, K; Higuchi, I; Hokezu, Y; Inose, M; Izumo, S; Osame, M; Yoshimine, K1

Trials

2 trial(s) available for mizoribine and Familial Spastic Paraparesis, Htlv-1-Associated

ArticleYear
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.
    Journal of neurovirology, 1996, Volume: 2, Issue:5

    Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antiviral Agents; Ascorbic Acid; Azathioprine; Danazol; Erythromycin; Estrogen Antagonists; Female; Fosfomycin; Glycerol; Human T-lymphotropic virus 1; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Immunosuppressive Agents; Injections, Intramuscular; Injections, Intravenous; Injections, Spinal; Interferon-gamma; Leukapheresis; Male; Methylprednisolone; Middle Aged; Paraparesis, Tropical Spastic; Pentoxifylline; Plasmapheresis; Propiophenones; Respiratory Therapy; Ribonucleosides; Sulfasalazine; Thyrotropin-Releasing Hormone; Vasodilator Agents

1996
[A study of clinical symptoms, muscle pathology, therapeutic response, and prognosis of myositis in patients with HTLV-1 associated myelopathy (HAM)].
    Rinsho shinkeigaku = Clinical neurology, 1999, Volume: 39, Issue:8

    Topics: Adult; Aged; Anti-Inflammatory Agents; Atrophy; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Muscle, Skeletal; Myositis; Necrosis; Paraparesis, Tropical Spastic; Prednisolone; Prognosis; Ribonucleosides; Treatment Outcome

1999